About the product
SORANIB or Sorafenat 200mg :
Sorafenib is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Sorafenib is a small molecular inhibitor of several Tyrosine protein kinases. (Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous). Sorafenib works along the multiple signaling pathways to block cell proliferation and tumor angiogenesis. It blocks the receptor tyrosine kinases VEGFR (Vascular Endothelial Growth Factor Receptor) and PDGFR (Platelet Derived Growth Factor Receptor) and the RAF serine/threonine kinases along the RAF/MEK/ERK pathway.
Indications :
RCC – Locally Advanced / Metastatic clear cell Renal cell carcinoma in patients, who have failed or unsuitable for cytokine therapy.
HCC – Unresectable hepatocellular carcinoma.
Dosage & Usage :
400mg – twice daily.
High fat meal may decrease oral bioavailability of Sorafenib.
Orally at least 1 hour before or 2 hours after a meal.
Drug Interactions :
Potential pharmacokinetic interaction with doxorubicin and irinotecan (increased area under the serum concentration-time curve [AUC] of doxorubicin and of irinotecan and its active metabolite SN-38).
Does not appear to affect the pharmacokinetics of gemcitabine or oxaliplatin.
Side Effects :
• Hypophosphatemia, Diarrhea, Increased Lipase Concentrations, Rash/Desquamation, Fatigue,
• Hand-foot Syndrome,
• Increased Amylase Concentrations,
• Alopecia,
• Nausea, Lymphopenia, Pruritus, Neutropenia, Hypertension, Anorexia, Vomiting, Constipation, Hemorrhage Dyspnea, Cough, Sensory Neuropathy, Dry Skin, Pain (Abdominal, Joint, Headache, Mouth, Bone, And Tumor), Weight Loss, Erythema, Asthenia, And Leukopenia
Note:
SORANIB is to be used under proper medical guidance and advice.
Sorafenib is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
Sorafenib is a small molecular inhibitor of several Tyrosine protein kinases. (Protein kinases are overactive in many of the molecular pathways that cause cells to become cancerous). Sorafenib works along the multiple signaling pathways to block cell proliferation and tumor angiogenesis. It blocks the receptor tyrosine kinases VEGFR (Vascular Endothelial Growth Factor Receptor) and PDGFR (Platelet Derived Growth Factor Receptor) and the RAF serine/threonine kinases along the RAF/MEK/ERK pathway.
Indications :
RCC – Locally Advanced / Metastatic clear cell Renal cell carcinoma in patients, who have failed or unsuitable for cytokine therapy.
HCC – Unresectable hepatocellular carcinoma.
Dosage & Usage :
400mg – twice daily.
High fat meal may decrease oral bioavailability of Sorafenib.
Orally at least 1 hour before or 2 hours after a meal.
Drug Interactions :
Potential pharmacokinetic interaction with doxorubicin and irinotecan (increased area under the serum concentration-time curve [AUC] of doxorubicin and of irinotecan and its active metabolite SN-38).
Does not appear to affect the pharmacokinetics of gemcitabine or oxaliplatin.
Side Effects :
• Hypophosphatemia, Diarrhea, Increased Lipase Concentrations, Rash/Desquamation, Fatigue,
• Hand-foot Syndrome,
• Increased Amylase Concentrations,
• Alopecia,
• Nausea, Lymphopenia, Pruritus, Neutropenia, Hypertension, Anorexia, Vomiting, Constipation, Hemorrhage Dyspnea, Cough, Sensory Neuropathy, Dry Skin, Pain (Abdominal, Joint, Headache, Mouth, Bone, And Tumor), Weight Loss, Erythema, Asthenia, And Leukopenia
Note:
SORANIB is to be used under proper medical guidance and advice.
Contact with supplier
Company